(NASDAQ: RNXT) Renovorx's forecast annual revenue growth rate of 188.41% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Renovorx's revenue in 2026 is $1,489,000.On average, 6 Wall Street analysts forecast RNXT's revenue for 2026 to be $147,429,066, with the lowest RNXT revenue forecast at $122,128,452, and the highest RNXT revenue forecast at $166,415,801. On average, 6 Wall Street analysts forecast RNXT's revenue for 2027 to be $566,760,804, with the lowest RNXT revenue forecast at $198,887,177, and the highest RNXT revenue forecast at $1,095,097,148.
In 2028, RNXT is forecast to generate $1,760,895,648 in revenue, with the lowest revenue forecast at $955,425,133 and the highest revenue forecast at $2,251,935,008.